Compare IPCA Labs with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs STERLING BIOTECH - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS STERLING BIOTECH IPCA LABS/
STERLING BIOTECH
 
P/E (TTM) x 22.1 -0.4 - View Chart
P/BV x 4.3 0.0 30,069.4% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   STERLING BIOTECH
EQUITY SHARE DATA
    IPCA LABS
Mar-18
STERLING BIOTECH
Dec-13
IPCA LABS/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs69511 6,622.9%   
Low Rs4003 11,764.7%   
Sales per share (Unadj.) Rs260.226.8 970.6%  
Earnings per share (Unadj.) Rs19.0-15.0 -126.8%  
Cash flow per share (Unadj.) Rs33.1-5.5 -605.1%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs213.054.9 388.2%  
Shares outstanding (eoy) m126.20267.87 47.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.10.3 811.9%   
Avg P/E ratio x28.9-0.5 -6,212.9%  
P/CF ratio (eoy) x16.6-1.3 -1,302.4%  
Price / Book Value ratio x2.60.1 2,030.1%  
Dividend payout %5.30-   
Avg Mkt Cap Rs m69,1201,862 3,712.7%   
No. of employees `00013.31.4 978.9%   
Total wages/salary Rs m7,359547 1,345.8%   
Avg. sales/employee Rs Th2,477.45,303.3 46.7%   
Avg. wages/employee Rs Th555.2403.8 137.5%   
Avg. net profit/employee Rs Th180.6-2,959.0 -6.1%   
INCOME DATA
Net Sales Rs m32,8367,181 457.3%  
Other income Rs m41843 981.2%   
Total revenues Rs m33,2547,223 460.4%   
Gross profit Rs m4,505947 475.7%  
Depreciation Rs m1,7772,543 69.9%   
Interest Rs m2404,377 5.5%   
Profit before tax Rs m2,905-5,931 -49.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m511-1,924 -26.6%   
Profit after tax Rs m2,394-4,007 -59.8%  
Gross profit margin %13.713.2 104.0%  
Effective tax rate %17.632.4 54.2%   
Net profit margin %7.3-55.8 -13.1%  
BALANCE SHEET DATA
Current assets Rs m19,45514,335 135.7%   
Current liabilities Rs m10,07649,809 20.2%   
Net working cap to sales %28.6-494.0 -5.8%  
Current ratio x1.90.3 670.9%  
Inventory Days Days98403 24.3%  
Debtors Days Days67171 39.2%  
Net fixed assets Rs m20,26055,432 36.5%   
Share capital Rs m252268 94.2%   
"Free" reserves Rs m26,63313,935 191.1%   
Net worth Rs m26,88614,701 182.9%   
Long term debt Rs m2,3409,478 24.7%   
Total assets Rs m41,17373,988 55.6%  
Interest coverage x13.1-0.4 -3,689.2%   
Debt to equity ratio x0.10.6 13.5%  
Sales to assets ratio x0.80.1 821.7%   
Return on assets %6.40.5 1,277.4%  
Return on equity %8.9-27.3 -32.7%  
Return on capital %10.8-6.4 -167.5%  
Exports to sales %47.625.9 183.9%   
Imports to sales %14.90.2 8,753.9%   
Exports (fob) Rs m15,6421,860 841.1%   
Imports (cif) Rs m4,88412 40,029.5%   
Fx inflow Rs m15,6421,860 841.1%   
Fx outflow Rs m4,88425 19,620.7%   
Net fx Rs m10,7591,835 586.3%   
CASH FLOW
From Operations Rs m3,4111,719 198.5%  
From Investments Rs m-1,354-3,148 43.0%  
From Financial Activity Rs m-1,3041,426 -91.5%  
Net Cashflow Rs m753-3 -22,152.9%  

Share Holding

Indian Promoters % 45.9 33.9 135.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 0.0 -  
FIIs % 25.3 9.9 255.6%  
ADR/GDR % 0.0 16.9 -  
Free float % 17.4 39.3 44.3%  
Shareholders   36,892 21,482 171.7%  
Pledged promoter(s) holding % 2.1 55.9 3.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   WYETH LTD  SANOFI INDIA  ALEMBIC PHARMA  SUN PHARMA  NOVARTIS  

Compare IPCA LABS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends above 39,000-Mark; Automobile and Banking Stocks Witness Buying(Closing)

Extending gains to the fifth day, Indian share markets rose sharply during the afternoon session and ended on a strong note.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Oct 17, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS